​

Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MIRM Stock Forecast

Mirum Pharmaceuticals (MIRM) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $70.00, with a high of $70.00 and a low of $70.00. This represents a 80.65% increase from the last price of $38.75.

$20 $30 $40 $50 $60 $70 High: $70 Avg: $70 Low: $70 Last Closed Price: $38.75

MIRM Stock Rating

Mirum Pharmaceuticals stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 1 Strong Buy (6.67%), 14 Buy (93.33%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 14 1 Strong Sell Sell Hold Buy Strong Buy

MIRM Price Target Upside V Benchmarks

TypeNameUpside
StockMirum Pharmaceuticals80.65%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$53.88
Last Closing Price$38.75$38.75$38.75
Upside/Downside--39.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2536---9
Mar, 2546---10
Feb, 2546---10
Jan, 2547---11
Dec, 2447---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Dae Gon HaStifel Nicolaus$70.00$40.5572.63%80.65%
Aug 08, 2024Brian SkorneyRobert W. Baird$44.00$38.9612.94%13.55%
Jun 17, 2024Gavin Clark-GartnerEvercore ISI$62.00$33.0087.88%60.00%
Jun 17, 2024Michael E UlzMorgan Stanley$57.00$33.0072.73%47.10%
Jun 17, 2024Ed ArceH.C. Wainwright$66.00$30.99112.97%70.32%
Jun 17, 2024Brian SkorneyRobert W. Baird$39.00$29.7131.27%0.65%
May 23, 2024Joshua SchimmerCantor Fitzgerald$45.00$25.7574.76%16.13%
Apr 16, 2024Dae Gon HaStifel Nicolaus$48.00$24.0199.92%23.87%
Mar 14, 2024Ed ArceH.C. Wainwright$58.00$28.17105.89%49.68%
Jan 10, 2023Leerink Partners$39.00$20.0294.81%0.65%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2024H.C. WainwrightBuyBuyhold
Aug 08, 2024Cantor FitzgeraldOverweightOverweighthold
Jun 18, 2024JMP SecuritiesOutperformOutperformhold
Jun 17, 2024Evercore ISIOutperformOutperformhold
Jun 17, 2024Morgan StanleyOverweightOverweighthold
Jun 17, 2024H.C. WainwrightBuyBuyhold
Jun 03, 2024CitigroupBuyBuyhold
May 23, 2024Cantor FitzgeraldOverweightOverweighthold
May 09, 2024Leerink PartnersBuyBuyhold
Apr 17, 2024Leerink PartnersBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.09$-2.77$-4.01$-4.00$-1.85----
Avg Forecast$-3.35$-4.48$-4.03$-3.37$-1.62$-0.62$0.62$2.92$4.97
High Forecast$-3.07$-4.10$-3.79$-3.07$-0.43$0.83$4.99$6.98$5.97
Low Forecast$-3.90$-5.21$-4.65$-3.62$-1.98$-1.28$-1.13$0.49$4.54
Surprise %22.09%-38.17%-0.50%18.69%14.20%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$19.14M$77.06M$186.37M$336.89M----
Avg Forecast$10.00M$78.42M$76.00M$184.64M$333.95M$422.98M$521.39M$718.97M$919.96M
High Forecast$11.25M$88.19M$84.88M$186.67M$336.76M$483.39M$521.39M$830.15M$1.06B
Low Forecast$9.34M$73.23M$72.47M$179.31M$332.51M$396.78M$521.39M$670.45M$857.89M
Surprise %--75.60%1.40%0.94%0.88%----

Net Income Forecast

$-250M $-140M $-30M $80M $190M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-103.27M$-83.99M$-135.66M$-163.41M$-87.94M----
Avg Forecast$-137.15M$-183.22M$-164.93M$-136.73M$-49.23M$-36.95M$44.32M$162.92M$203.34M
High Forecast$-125.35M$-167.46M$-154.97M$-125.39M$-17.48M$33.78M$203.99M$285.38M$244.21M
Low Forecast$-159.37M$-212.90M$-189.98M$-148.08M$-80.98M$-52.35M$-46.16M$20.03M$185.50M
Surprise %-24.70%-54.16%-17.74%19.51%78.64%----

MIRM Forecast FAQ

Is Mirum Pharmaceuticals stock a buy?

Mirum Pharmaceuticals stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mirum Pharmaceuticals is a favorable investment for most analysts.

What is Mirum Pharmaceuticals's price target?

Mirum Pharmaceuticals's price target, set by 15 Wall Street analysts, averages $70 over the next 12 months. The price target range spans from $70 at the low end to $70 at the high end, suggesting a potential 80.65% change from the previous closing price of $38.75.

How does Mirum Pharmaceuticals stock forecast compare to its benchmarks?

Mirum Pharmaceuticals's stock forecast shows a 80.65% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Mirum Pharmaceuticals over the past three months?

  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Mirum Pharmaceuticals’s EPS forecast?

Mirum Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.62, marking a -66.49% decrease from the reported $-1.85 in 2024. Estimates for the following years are $0.62 in 2026, $2.92 in 2027, and $4.97 in 2028.

What is Mirum Pharmaceuticals’s revenue forecast?

Mirum Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $422.98M, reflecting a 25.55% increase from the reported $336.89M in 2024. The forecast for 2026 is $521.39M, followed by $718.97M for 2027, and $919.96M for 2028.

What is Mirum Pharmaceuticals’s net income forecast?

Mirum Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-36.952M, representing a -57.98% decrease from the reported $-87.942M in 2024. Projections indicate $44.32M in 2026, $162.92M in 2027, and $203.34M in 2028.